Drug Profile
Research programme: T-cell therapies - Adaptimmune
Alternative Names: Affinity-enhanced T-cell receptors - Adaptimmune; Allogeneic SPEAR T-cell; Allogenic T-cell therapies - Adaptimmune; Cytotoxic T-lymphocytes stimulants - Adaptimmune; PRAME; Preferentially expressed antigen in melanomaLatest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator Adaptimmune
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
- No development reported Diabetes mellitus; Hepatitis C; Immunological disorders
Most Recent Events
- 06 Mar 2023 T-cell therapies is still in preclinical trials for Cancer in the UK (IV, Infusion)
- 31 Dec 2022 GlaxoSmithKline terminates its licence for T-cell therapies worldwide
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (IV, Infusion)